Cargando…

Modulator Therapy in Cystic Fibrosis Patients with cis Variants in F508del Complex Allele: A Short-Term Observational Case Series

Previous studies reported the influence of cis variants in F508del cystic fibrosis (CF) patients in their responses to CFTR modulators. The current study is a prospective, observational study involving three patients with CF and pancreatic insufficiency, carrying a complex allele including F508del w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Terlizzi, Vito, Centrone, Claudia, Ferrari, Beatrice, Castellani, Chiara, Gunawardena, Tarini N. A., Taccetti, Giovanni, Laselva, Onofrio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504164/ https://www.ncbi.nlm.nih.gov/pubmed/36143206 http://dx.doi.org/10.3390/jpm12091421

Ejemplares similares

Dornase alfa in Cystic Fibrosis: indications, comparative studies and effects on lung clearance index
por: Terlizzi, Vito, et al.
Publicado: (2022)

G378X‐I148T CFTR variant: A new complex allele in a cystic fibrosis newborn with pancreatic insufficiency
por: Terlizzi, Vito, et al.
Publicado: (2022)

Effect of Dornase Alfa on the Lung Clearance Index in Children with Cystic Fibrosis: A Lesson from a Case Series
por: Terlizzi, Vito, et al.
Publicado: (2022)

Elexacaftor–Tezacaftor–Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype
por: Comegna, Marika, et al.
Publicado: (2021)

Anticipating New Treatments for Cystic Fibrosis: A Global Survey of Researchers
por: Cabral, Bernardo, et al.
Publicado: (2022)

Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Three Subjects with the Cystic Fibrosis Genotype Phe508del/Unknown and Advanced Lung Disease
por: Terlizzi, Vito, et al.
Publicado: (2021)

Cystic fibrosis in Tuscany: evolution of newborn screening strategies over time to the present
por: Botti, Matteo, et al.
Publicado: (2021)

Clinical and Genotypical Features of False-Negative Patients in 26 Years of Cystic Fibrosis Neonatal Screening in Tuscany, Italy
por: Taccetti, Giovanni, et al.
Publicado: (2020)

Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation and Advanced Lung Disease: A 48-Week Observational Study
por: Carnovale, Vincenzo, et al.
Publicado: (2022)

Hypertonic saline in people with cystic fibrosis: review of comparative studies and clinical practice
por: Terlizzi, Vito, et al.
Publicado: (2021)

Impact of Pancreatitis-Associated Protein on Newborn Screening Outcomes and Detection of CFTR-Related Metabolic Syndrome (CRMS)/Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID): A Monocentric Prospective Pilot Experience
por: Bianchimani, Chiara, et al.
Publicado: (2022)

Decoding F508del Misfolding in Cystic Fibrosis
por: Wang, Xiaodong Robert, et al.
Publicado: (2014)

Comparison between Gibson–Cooke and Macroduct Methods in the Cystic Fibrosis Neonatal Screening Program and in Subjects Who Are Cystic Fibrosis Screen-Positive with an Inconclusive Diagnosis
por: Dolce, Daniela, et al.
Publicado: (2023)

Ex vivo model predicted in vivo efficacy of CFTR modulator therapy in a child with rare genotype
por: Terlizzi, Vito, et al.
Publicado: (2021)

Concomitant Use of Elexacaftor/Tezacaftor/Ivacaftor and Etanercept in a Cystic Fibrosis Patient with Juvenile Idiopathic Arthritis
por: Orsini, Sara Immacolata, et al.
Publicado: (2023)

Clinical characteristics and outcome of SARS –CoV-2 infection in patients with cystic fibrosis managed at home
por: Terlizzi, V., et al.
Publicado: (2022)

Elexacaftor/Tezacaftor/Ivacaftor Accelerates Wound Repair in Cystic Fibrosis Airway Epithelium
por: Laselva, Onofrio, et al.
Publicado: (2022)

Auxological and Endocrinological Features in Children and Adolescents with Cystic Fibrosis
por: Ferrari, Vittorio, et al.
Publicado: (2022)

Early Effects of Elexacaftor-Tezacaftor-Ivacaftor Therapy on Magnetic Resonance Imaging in Patients with Cystic Fibrosis and Advanced Lung Disease
por: Macconi, Letizia, et al.
Publicado: (2022)

Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles
por: Taylor-Cousar, Jennifer L., et al.
Publicado: (2019)

Allele-Specific Prevention of Nonsense-Mediated Decay in Cystic Fibrosis Using Homology-Independent Genome Editing
por: Erwood, Steven, et al.
Publicado: (2020)

CFTR-F508 pigs provide new clues to cystic fibrosis
Publicado: (2011)

Editorial: Mechanisms of Novel Drugs and Gene Modifiers in the Treatment of Cystic Fibrosis
por: Veit, Guido, et al.
Publicado: (2022)

Advances in Preclinical In Vitro Models for the Translation of Precision Medicine for Cystic Fibrosis
por: Silva, Iris A. L., et al.
Publicado: (2022)

Manipulating proteostasis to repair the F508del-CFTR defect in cystic fibrosis
por: Esposito, Speranza, et al.
Publicado: (2016)

ΔF508 CFTR interactome remodeling promotes rescue of Cystic Fibrosis
por: Pankow, Sandra, et al.
Publicado: (2015)

P.F508del editing in cells from cystic fibrosis patients
por: Smirnikhina, Svetlana A., et al.
Publicado: (2020)

A new platform for high-throughput therapy testing on iPSC-derived lung progenitor cells from cystic fibrosis patients
por: Jiang, Jia Xin, et al.
Publicado: (2021)

A Multicentre Italian Study on the Psychological Impact of an Inconclusive Cystic Fibrosis Diagnosis after Positive Neonatal Screening
por: Tosco, Antonella, et al.
Publicado: (2023)

High frequency of complex CFTR alleles associated with c.1521_1523delCTT (F508del) in Russian cystic fibrosis patients
por: Petrova, Nika V., et al.
Publicado: (2022)

Azithromycin reduces spontaneous and induced inflammation in ΔF508 cystic fibrosis mice
por: Legssyer, Rachida, et al.
Publicado: (2006)

Screening for F508del as a first step in the molecular diagnosis of cystic fibrosis,
por: Marson, Fernando Augusto de Lima, et al.
Publicado: (2013)

Impact of MIF Gene Promoter Polymorphism on F508del Cystic Fibrosis Patients
por: Melotti, Paola, et al.
Publicado: (2014)

Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis
por: Sermet-Gaudelus, Isabelle, et al.
Publicado: (2018)

Olfactory dysfunction in people with cystic fibrosis with at least one copy of F508del
por: Beswick, Daniel M., et al.
Publicado: (2022)

Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors
por: Amico, Giulia, et al.
Publicado: (2019)

Activity of lumacaftor is not conserved in zebrafish Cftr bearing the major cystic fibrosis‐causing mutation
por: Laselva, Onofrio, et al.
Publicado: (2019)

Olive Leaf Extract (OLE) as a Novel Antioxidant That Ameliorates the Inflammatory Response in Cystic Fibrosis
por: Allegretta, Caterina, et al.
Publicado: (2023)

Clinical Consequences and Functional Impact of the Rare S737F CFTR Variant and Its Responsiveness to CFTR Modulators
por: Terlizzi, Vito, et al.
Publicado: (2023)

P163 Effects of the SARS-CoV-2 pandemic on attendance at the cystic fibrosis centre and the definition of the microbiological status of cystic fibrosis patients in Tuscany
por: Dolce, D., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_k9a8t3rng1qag5s26hau77vec8